Eupraxia Pharmaceuticals Inc. (EPRX.TO)
CAD 4.59
(-2.34%)
CAD 4.59
(-2.34%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 26.72 Million CAD | 3.27% |
| 2022 | 25.87 Million CAD | -17.12% |
| 2021 | 31.22 Million CAD | 2047.93% |
| 2020 | 1.45 Million CAD | -55.75% |
| 2019 | 3.28 Million CAD | 12.92% |
| 2018 | 2.9 Million CAD | -50.2% |
| 2017 | 5.84 Million CAD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 49.57 Million CAD | 144.63% |
| 2024 Q2 | 34.17 Million CAD | -31.07% |
| 2023 Q4 | 20.26 Million CAD | -41.0% |
| 2023 Q1 | 19.87 Million CAD | -23.18% |
| 2023 Q3 | 34.35 Million CAD | 68.79% |
| 2023 FY | 26.72 Million CAD | 3.27% |
| 2023 Q2 | 20.35 Million CAD | 2.39% |
| 2022 Q4 | 25.87 Million CAD | -17.73% |
| 2022 Q3 | 31.45 Million CAD | -15.14% |
| 2022 FY | 25.87 Million CAD | -17.12% |
| 2022 Q2 | 37.06 Million CAD | 36.25% |
| 2022 Q1 | 27.19 Million CAD | -12.88% |
| 2021 Q1 | 32.56 Million CAD | 2140.0% |
| 2021 FY | 31.22 Million CAD | 2047.93% |
| 2021 Q3 | 34.9 Million CAD | -6.01% |
| 2021 Q4 | 31.22 Million CAD | -10.56% |
| 2021 Q2 | 37.14 Million CAD | 14.07% |
| 2020 Q4 | 1.45 Million CAD | 57.89% |
| 2020 Q3 | 920.65 Thousand CAD | 0.0% |
| 2020 FY | 1.45 Million CAD | -55.75% |
| 2019 FY | 3.28 Million CAD | 12.92% |
| 2019 Q4 | 3.28 Million CAD | 0.0% |
| 2018 FY | 2.9 Million CAD | -50.2% |
| 2017 FY | 5.84 Million CAD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Appili Therapeutics Inc. | 1.49 Million CAD | -1693.008% |
| Helix BioPharma Corp. | 1.48 Million CAD | -1694.698% |
| Microbix Biosystems Inc. | 35.65 Million CAD | 25.047% |
| Medicenna Therapeutics Corp. | 19.13 Million CAD | -39.663% |
| Satellos Bioscience Inc. | 44.29 Million CAD | 39.674% |
| Oncolytics Biotech Inc. | 38.82 Million CAD | 31.162% |
| Sernova Corp. | 22.1 Million CAD | -20.881% |